Table 4.

Comparison of flow-mediated dilation (FMD) and nitrate-mediated dilation (NMD) in gout subjects with versus without specific demographic and comorbid risk factors

	FMD			NMD
Condition	Condition absent	Condition present	p value	Condition absent	Condition present	p value
African American (15,15)	2.36 ± 0.81	1.32 ± 0.19	0.35	19.48 ± 2.45	12.22 ± 0.63	0.04
Smoking (24,10)	2.33 ± 0.87	1.86 ± 1.02	0.70	15.99 ± 1.62	18.78 ± 4.6	0.49
CAD (27,7)	2.07 ± 0.51	2.70 ± 1.59	0.64	15.56 ± 1.89	21.89 ± 2.31	0.16
CKD (8,26)	2.28 ± 1.15	2.17 ± 0.59	0.93	18.31 ± 2.76	16.04 ± 2.05	0.57
HTN (10,24)	1.72 ± 0.9	2.40 ± 0.64	0.57	20.98 ± 3.41	15.00 ± 0.11	0.11
HL (17,17)	1.20 ± 0.63	3.19 ± 0.77	0.06	17.41 ± 2.28	15.00 ± 0.64	0.66

Numbers in parentheses after each stratification category correspond to numbers of patients in the gout and control groups, respectively

CAD coronary artery disease, CKD chronic kidney disease, HTN hypertension, HL hyperlipidemia